Jean-Pierre Armand MD, MSc, is certified in Medical Oncology (University of Toulouse III and Paris XI). He was recently General Director of the Institut Claudius Regaud in Toulouse.
Chief Executive Officer
MD PhD, is medical oncologist by training and is currently working at Institut Gustave Roussy as head of the Hematology department and head of the early drug development tumor board.
Chief Scientific Officer
Obtained a PhD from Paris VI University in 2005 focused on metabolic disorders, and an EMBO long-term postdoctoral fellowship at ETH-Zürich for a project of pancreatic cancer biomarker.
Deputy Chief Scientific Officer
Obtained a PhD from the Paris VII University in 2003. His research studies at the Pasteur Institute were dedicated to the analysis of the immunogenetic and viral factors controlling the evolution of papillomavirus-associated tumors
Jean-Paul Alves, BSc in Economy, Graduated from EM Lyon and Post Graduated in Managerial Accounting, Chartered Accounting and Tax, joined Pegascy in 2020 as Chief Financial Officer.
MD, PhD, is pediatric oncologist heading the Pediatric Early Drug Development Program of Institut Gustave Roussy.
Olivier Delattre : MD, PhD was trained in pediatric oncology and genetics. His research area mainly investigates the genetic and biology of pediatric cancers.
Pierre Busson is a Senior Research Scientist at the CNRS and Gustave Roussy (DR1 CNRS, UMR 9018, Villejuif, France). He obtained his M.D. in 1983 and his Ph.D. in Virology in 1990 from Paris University.
Alexandra Leary is a Medical Oncologist and Translational Researcher specializing in gynaecological tumors at Gustave Roussy
Christophe Massard, Head of Pegascy’s SAB, ex-Head of In-patient Unit at Drug Development Department (DITEP), Gustave Roussy
Patricia LoRusso, Associate Director of Experim. Therapeutics at Yale Cancer Center (US) More than 25 years of expertise in medical oncology
Josep Tabernero, ESMO President, Head of the Medical Oncology Department at the Vall d’Hebron Hospital Campus (Barcelone ,Spain)
Thimothy Yap, Medical Oncologist at the Un. of Texas MD Anderson Cancer Center (US)
Udai Banerji, Deputy Director of the Drug Development Unit at The ICR (London, UK)
Jean-Pierre Bizzari, ex-Executive Vice-President, Group Head, and Clinical Oncology Development (U.S., Europe, Asia)
Jean-Yves Blay, CEO of the Centre Leon Berard (Lyon ,France) and President of UNICANCER Professor in Medical Oncology
Susan Bates, Director, Translational Cancer Medicine, Division of Hematology/Oncology of the Herbert Irving Comprehensive Cancer Center
Dr. Melero started out in biomedical research as a resident of immunology at the prestigious department of this specialty in Hospital Universitario de la Princesa (Madrid).
Professor Emeritus, Medical Oncology, University of Nantes, France; Senior Advisor, Integrated Centers of Oncology (ICO), Nantes, France Jean-Yves Douillard trained at the Medical School...
Professor Jean-Hugues Trouvin graduated in Pharmacy and received his State Doctorate in Pharmacology from the University of Paris.
Aurelio ZERIAL is doctor in Biology (University of Trieste, Italy) and PhD in Biochemistry (1978 -Wesleyan University, USA).
After studying pharmacy at Grenoble and Lyon Universities, I am now living in Normandy with my family.
Florence Allouche: Founder and President of MYRPHARM ADVISORS, a consulting firm helping translational academic research
Antoine (Tony) Awad joined Synlogic in December 2018 as Head of Technical Operations and is responsible for process sciences and manufacturing functions for the Company.
Dr Alex Lugovskoy has joined Atlas Venture as Entrepreneur-in-Residence in January 2022.